Nociceptive vs neuropathic pain: why cannabinoids work differently for each type

Pain is not a single mechanism. Nociceptive pain arises when tissue is damaged, while neuropathic pain occurs when the nervous system itself is damaged. This distinction determines the choice of medications, as preparations effective for one type may be useless for the other, and the patient then hears that the drug "did not work." Cannabinoids are increasingly appearing in this conversation, usually with the promise that they work on both types of pain simultaneously. A systematic review published in JAMA included 79 studies involving 6462 participants and considered the evidence for their effect in chronic pain to be of moderate quality. This article explains how the two types of pain differ, what studies on cannabinoids say about humans, and where popular explanations diverge from the literature.

KEY INFORMATION
• A review of 79 studies involving 6462 people found moderate quality evidence for the effect of cannabinoids in chronic pain and spasticity (Whiting et al., JAMA 2015).
• A meta-analysis of 24 randomized studies indicates neuropathic pain as the indication where the effect is most evident, but the authors themselves call its clinical significance uncertain.
• The popular division into CB receptors for neuropathic pain and TRPV1 for inflammatory pain is an oversimplification: in Xiong's work, the strength of the analgesic effect did not correlate with affinity for CB1 or CB2.
• Evidence for topical CBD in arthritis comes from rat models, not from human studies.
• EFSA stated in 2026 that the safety of CBD cannot be established in people taking medications, and this is a typical reader of a post about chronic pain.

What is nociceptive pain?

Nociceptive pain is a warning signal triggered by actual tissue damage. Nociceptors, which are specialized nerve endings scattered in the skin, muscles, joints, and internal organs, respond to mechanical, thermal, and chemical stimuli. Damage releases inflammatory mediators: prostaglandins, bradykinin, substance P. They stimulate nociceptors, and the signal travels through A-delta and C fibers to the spinal cord, and from there upwards.

This type of pain has a clear localization. It intensifies with touch or movement at the site of injury and usually subsides as healing occurs. This is how a fracture, sprain, surgical wound, burn, and inflammatory joint diseases, including rheumatoid arthritis and osteoarthritis, feel. Non-steroidal anti-inflammatory drugs work well here because they directly target the inflammatory mediators that drive this pain.

It is worth noting one distinction within the category itself. Nociceptive pain can be inflammatory, as in arthritis, or post-traumatic and short-lived, as after a procedure. All the literature on cannabinoids referenced in this article concerns chronic pain. Research on acute postoperative pain is scarce and does not allow for conclusions in either direction, so extending results from chronic pain to acute injury is an overreach.

What is neuropathic pain?

Neuropathic pain arises when the nervous system itself, either peripheral or central, is damaged or functioning abnormally. There is no active tissue injury that a nociceptor could report. Instead, damaged neurons generate spontaneous pain signals. Described mechanisms include neuronal hyperexcitability, central sensitization, demyelination of fibers, and pathological functioning of ion channels.

The description of the ailment is also clear. Patients report burning, stabbing, and electric shock sensations. Allodynia, which is pain triggered by a stimulus that normally does not cause pain, and hyperalgesia, which is an excessive reaction to a painful stimulus, occur. Pain persists despite the absence of active injury and is most often chronic. Typical causes include diabetic neuropathy, postherpetic neuralgia, phantom pain, chemotherapy-induced neuropathy, and multiple sclerosis.

Classical pain medications perform worse here than with nociceptive pain because they do not address the pathological activity of neurons. In clinical practice, neuron-stabilizing medications such as gabapentin, pregabalin, or duloxetine are used. This distinction is also important for evaluating cannabinoids, as it is precisely in neuropathic pain that meta-analyses see the most.

What are the practical differences between the two types of pain?

The table compares both types in terms of source, course, and response to treatment. Consciously, there is no row about receptors: the receptor-based division that circulates in consumer texts lacks support in the studies cited below. It is a simplified model, as chronic pain often has components of both types simultaneously.

The practical significance of this comparison is best seen during a medical interview. The way a patient describes their symptoms, the presence of allodynia, and the response to previous treatments are signals that guide the diagnosis one way or another, even before imaging studies are conducted. Read the row about evidence cautiously: it describes the state of the literature, not the expected effect on a specific individual.

How does CBD affect pain with an inflammatory component?

The most specific data concerns local administration and comes from an animal model. Hammell and colleagues induced unilateral knee joint inflammation in rats and then applied CBD gel for four days (European Journal of Pain, 2016). The joint circumference, immune cell infiltration, and synovial membrane thickness decreased depending on the dose, while the exploratory behavior of the animals remained unchanged, which the authors interpreted as a lack of impact on higher brain functions.

One aspect of this study is often misrepresented in consumer texts. The claim that transdermal application works solely locally and does not enter the bloodstream is repeated. The study states the opposite: the authors measured CBD concentration in plasma and found a linear increase with the dose in the lower range of tested gels. Therefore, transdermal CBD enters circulation, bypassing the digestive tract and first-pass effect. This is an argument for more stable concentrations, not for a lack of absorption.

The limitation of this study is obvious and must be stated plainly. It involves rodents, four days of observation, and artificially induced joint inflammation. The result justifies further research on topical preparations, not the transfer of numbers to humans with knee osteoarthritis. We discuss the boundary between evidence and promise more broadly in the text about CBD for chronic pain.

What do we know about CBD for neuropathic pain?

The most frequently cited preclinical study in this area is also the one that most strongly undermines the popular explanation. Xiong and colleagues administered CBD and its derivatives to rodents with chronic inflammatory and neuropathic pain (The Journal of Experimental Medicine, 2012). Pain clearly decreased, and this occurred without the development of tolerance to the analgesic effect, which is not obvious with pain medications.

However, the mechanism turned out to be different from the commonly held version. The authors compared eleven structurally similar cannabinoids and found that the strength of their analgesic effect was associated with the enhancement of alpha-3 glycine receptor responses, not with affinity for CB1 and CB2 receptors. In mice lacking the alpha-3 glycine receptor, the analgesic effect completely disappeared. NMR spectroscopic analysis showed direct binding of CBD to residue S296 in the third transmembrane domain of this receptor.

For the reader, this means one thing. Sentences like "in neuropathic pain, CB1 and CB2 are active, while in inflammatory pain, TRPV1 and COX-2 are" sound precise but lack support in this literature. The TRPV1 receptor is indeed a target for CBD, and we describe it separately in connection with receptora kapsaicyny, but deriving from this division into two types of pain is adding a conclusion that the studies did not establish.

What do clinical studies on humans show?

The systematic review by Whiting and colleagues published in JAMA included 79 randomized studies and 6462 participants, of which only four studies were rated as having a low risk of systematic error (JAMA, 2015). In eight studies concerning pain, the percentage of individuals with relief was 37 percent for cannabinoids compared to 31 percent for placebo, with an odds ratio of 1.41 and a confidence interval from 0.99 to 2.00. This interval touches one, so the result is on the edge of significance. The authors' conclusion was: moderate quality evidence for chronic pain and spasticity.

The meta-analysis by Aviram and Samuelly-Leichtag reviewed 43 randomized studies involving 2437 patients, and 24 studies with 1334 patients qualified for the meta-analysis (Pain Physician, 2017). The overall effect size compared to placebo was -0.61 with a confidence interval from -0.78 to -0.43, and for inhaled administration, it was -0.93. The authors describe this evidence as limited. However, the authors caution that most individual studies did not show an effect, and the clinical significance of the result remains uncertain. Their conclusion points to neuropathic pain as an indication with the best, albeit still limited, basis.

A separate issue is the registration status. Nabiximols, a preparation combining THC and CBD, are approved for sale in Poland under the mutual recognition procedure, indicated for spasticity in multiple sclerosis. This is not a central registration with the European Medicines Agency nor a registration for neuropathic pain, although both formulations circulate in consumer texts. We discuss the neurological indication itself in connection with trigeminal neuralgia.

What is mixed pain?

Pure forms of both types are practically rarer than their mixture. Diabetic neuropathy combines nerve damage with vascular and inflammatory changes. Rheumatoid arthritis starts as inflammatory pain, but over the years adds secondary central sensitization, which is the neuropathic component. Back pain is often described as mixed precisely because both mechanisms overlap. Cancer pain looks similar, where the tumor's pressure on tissues coexists with nerve damage due to the disease or treatment.

This has practical consequences when reading studies. Research on cannabinoids usually recruits patients with chronic pain described by diagnosis rather than mechanism, so the study groups can be mixed. This is one of the reasons why aggregate results are heterogeneous, and authors of meta-analyses mention significant heterogeneity in studies. Therefore, the effect visible in one trial may come from a subgroup with a predominance of one mechanism, which a single study usually does not resolve. A cautious conclusion is as follows: distinguishing mechanisms is real and clinically useful, but data on cannabinoids are not yet precise enough to assign a separate efficacy profile to each type.

Why won't you find a dosage table here?

Chronic pain is a medical indication, and with a medical indication, we do not provide the number of milligrams that the reader could measure out. The reason is not formal. The EFSA panel in its 2026 position update derived a provisional safe dose of CBD at 0.0275 mg per kilogram of body weight per day, which is about 2 mg for a person weighing 70 kg, and specified that it applies only to supplements with at least 98 percent purity of CBD, without nanoparticles (EFSA Journal, 2026).

In the same document, the panel states directly that the safety of CBD cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in people taking medications. The last group describes the typical reader of an article on chronic pain. The hepatotoxic signal in human studies was, in the panel's assessment, more pronounced when used concurrently with other medications.

In addition, there are interactions. Brown and Winterstein reviewed the characteristics of registered CBD products and described the impact of substances on CYP3A4 and CYP2C19 as well as on P-glycoprotein, which are pathways for the metabolism and excretion of many commonly used medications (Journal of Clinical Medicine, 2019). Nearly half of CBD users reported adverse effects, including increased aminotransferase activity and drowsiness. This is a conversation to have with the attending physician, not something to resolve with a table on the internet.

Frequently Asked Questions

What is the difference between nociceptive and neuropathic pain?

Nociceptive pain is a reaction to actual tissue damage and usually subsides with healing. Neuropathic pain results from damage to the nervous system itself, persists chronically, and has a burning or electric character. The difference concerns the mechanism, so medications effective for one type may be ineffective for the other.

Does CBD help with neuropathic pain?

A meta-analysis of 24 randomized studies involving 1334 patients indicates neuropathic pain as the indication with the best basis among pain syndromes, but the authors themselves call the clinical significance of this result uncertain and note that most individual studies did not show an effect. This is too little to speak of efficacy and enough to continue researching.

Does CBD work for inflammatory joint pain?

Data primarily comes from animal models. In rats with induced knee joint inflammation, four days of using CBD gel reduced joint swelling and inflammatory infiltration depending on the dose. There is still a lack of randomized studies on topical CBD in degenerative disease in humans, so the result justifies research, not recommendations.

Why is there no dosage table in this article?

Because chronic pain is a medical indication. EFSA stated in 2026 that the safety of CBD cannot be established in people taking medications, pregnant and breastfeeding women, and individuals under 25 years of age. Dose selection in such situations is a decision for the attending physician, who knows the other medications being taken.

Can cannabinoids be combined with pain medications?

This requires consultation. CBD interacts with the enzymes CYP3A4 and CYP2C19 and with P-glycoprotein, affecting the metabolism and excretion pathways of many drugs. In the review by Brown and Winterstein, nearly half of users reported adverse effects, and the signal of liver damage was more pronounced when taken with other medications.

In summary: distinguishing nociceptive and neuropathic pain is real and significant for treatment, but the evidence for cannabinoids is not yet precise enough to assign a separate mechanism and separate efficacy to each type. The results we have pertain to chronic pain, are of moderate quality, and most strongly indicate neuropathic pain.

If you are looking for oral or sublingual products, you will find them in the category oils.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-08-05 · Aktualizacja: 2026-08-16